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Abstract
Background: Oxidative stress is recognized to be one of predisposing factor in the pathogenesis of COPD. The
oxidant/antioxidant imbalance is significantly pronounced in patients with COPD exacerbation. N-acetylcysteine
(NAC) seems to be able to reduce COPD exacerbations by modulating the oxidative stress in addition to its well-
known mucolytic activity, but there are discordant findings on the actual anti-oxidant activity of NAC.
Methods: The anti-oxidant effect of NAC and its impact on the inflammatory response have been pharmacologically
characterized on a human ex vivo model of COPD exacerbation induced by lipopolysaccharide (LPS).
Results: NAC prevented the desensitization induced by LPS incubation on the contractile tone in linear concentration-
response manner. Concentrations of NAC ≥1 μM reduced the pro-oxidant response (peroxidase activity, hydrogen
peroxide, malondialdehyde, nitric oxide), and improved the anti-oxidant response (total anti-oxidant capacity,
glutathione, superoxide dismutase) induced by LPS. Lower concentrations of NAC (<1 μM) did not modulate the
bronchial oxidative imbalance. Concentrations of NAC ≥300 μM inhibited the inflammatory response (release of IL-1β,
IL-8, and TNF-α) of human airways induced by the overnight stimulation with LPS, whereas lower concentrations of
NAC (≥1 μM) were sufficient to reduce the release of IL-6 elicited by LPS. Both the anti-oxidant effect and the anti-
inflammatory effect of NAC were inversely correlated with the release of NKA.
Conclusions: The findings of this study suggest that NAC may have a role in modulating the detrimental effect
induced by LPS in course of COPD exacerbation. It may elicit both anti-oxidant and anti-inflammatory effects when
administered at high concentrations.
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Background
Oxidative stress is recognized to be one of the critical
factors in the pathway by which cigarette smoke expos-
ure leads to disease [1]. It is not surprising, therefore,
that there is solid evidence of increased oxidative stress
in the airways of patients with chronic obstructive pul-
monary disease (COPD), which is increased further in
severe and very severe exacerbations of the disease and
is associated with increased neutrophil influx and
interleukin (IL)-8 levels during exacerbations [2]. The
documentation that the glutathione (GSH) levels are in-
creased in the bronchoalveolar lavage fluid (BALF) of
patients with stable COPD and are reduced during exac-
erbations compared with stable COPD [2] suggests that
the increase of lung GSH may be an attempt, albeit
insufficient, to counter excess oxidant production, at-
tempt totally inadequate during exacerbations due to the
excessive production of reactive oxygen species (ROS). It
is obvious that in this clinical condition, we must always
try to increase the GSH levels [1].
Two pivotal trials and a recent meta-analysis have
shown that N-acetylcysteine (NAC) is able to prevent
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COPD exacerbations [3–5]. NAC acts as a mucolytic,
antioxidant and anti-inflammatory agent [6]. The anti-
oxidant activity of NAC may be both direct (the free
sulfhydryl group may serve as a ready source of reducing
equivalents) and indirect (through replenishment of
intracellular GSH levels) antioxidant effects [1]. How-
ever, there are several conflicting in vitro and in vivo
findings on the real anti-oxidant activity of NAC, which,
in any case, seems to be mainly dose-dependent [7].
Therefore, the aim of this study has been to pharma-
cologically characterize the anti-oxidant effect of NAC
and its impact on the inflammatory response in a human
ex vivo model of COPD exacerbation induced by
lipopolysaccharide (LPS). Actually, since respiratory in-
fections are associated with the majority of COPD exac-
erbations and their severity, especially those with
bacterial co-infection, inhaled LPS provocation has been
demonstrated to be an effective model of COPD exacer-
bation [8, 9]. LPS, also called endotoxin, is a major pro-
inflammatory glycolipid component of the outer cell
membrane of Gram-negative bacteria associated with
the development and/or progression of many types of
lung diseases including COPD [10]. LPS inhalation is re-
lated with elevation of neutrophils, macrophages and
certain cytokines/chemokines in sputum and BALF, and
similar inflammatory changes are observed during exac-
erbations COPD.
Methods
Tissue collection and preparation
Macroscopically normal airways were obtained from 6
moderate-to-severe COPD patients (4 male, 2 female,
age 65.2 ± 5.8 years old) undergoing surgery for lung
cancer. Samples were taken from an area as far as pos-
sible from the malignancy. Tissues were placed into
Krebs-Henseleit buffer solution (KH) (NaCl, 119.0 mmol;
KCl, 5.4 mmol; CaCl2, 2.5 mmol; KH2PO4 mmol,
1.2 mmol; MgSO4, 1.2 mmol; NaHCO3, 25.0 mmol;
glucose, 11.7 mmol; pH 7.4) containing indomethacin
(5 μM) and transported to the Laboratory of Respiratory
Clinical Pharmacology at the University of Rome Tor
Vergata (Italy) from a surrounding hospital.
Ethical approval (RS 60.15, 2015) and informed con-
sent were consistent with the 2009 National Committee
of Bioethics, National Committee of Bio-safety, Biotech-
nology and Sciences (Italy) recommendations on the
collection of biological samples for research purposes,
the 2010 Italian ethical and legal recommendations
concerning the biobank and the research biorepository
(Istituto Nazionale dei Tumori — Independent Ethics
Committee, 2010), and the Comitato Nazionale per la
Biosicurezza, le Biotecnologie e le Scienze per la Vita
(Raccolta di campioni biologici a fini di ricerca, consenso
informato, 2009; available at: http://www.governo.it/
bioetica/gruppo_misto/Consenso_Informato_allegato_Pe
trini_2009.pdf ).
In our laboratory, airways were cut into rings (thick-
ness 1–2 mm; diameter 4–6 mm) and transferred into a
10 ml High Tech 8 Channels Manual Compact Organ
Bath system (Panlab Harvard Apparatus, Spain) contain-
ing KH-buffer (37 °C) and aerated with O2/CO2 (95:5%).
Tissues were allowed to equilibrate and the KH buffer
was constantly changed.
Preparation of drugs
The following compounds were used: GSH, indomethacin,
LPS from E. coli 0111:B4 and NAC. Compounds were dis-
solved in distilled water except for indomethacin, which
was dissolved in ethanol and then diluted in a KH buffer.
The maximal amount of ethanol (0.02%) did not influence
isolated tissue responses. Appropriate dilutions were ob-
tained in freshly prepared medium and stock solutions
stored at —80 °C until use. NAC dilutions were prepared
daily before experiments.
Tension measurement
Bronchial rings were connected to isometric force trans-
ducers Fort25 (WPI, UK). The signal was amplified by
Bridge Amplifiers for Biopac system, recorded and
analyzed with the Biopac interface software (16 + 16
channels). Tissues were mounted on hooks, and at-
tached with thread to a stationary rod and the other tied
with thread to an isometric force displacement trans-
ducer. Airways were allowed to equilibrate for 90 min
flushing with fresh KH buffer solution every 10 min.
Passive tension was determined by gentle stretching of
tissue (0.5–1.0 g) during equilibration. The isometric
change in tension was measured by the transducer and
the tissue responsiveness assessed by electrical field
stimulation (EFS) at 25 Hz. After that, rings ware
washed three times and allowed to stabilize.
COPD exacerbation model
Bronchial tissues were incubated overnight with KH buffer
solution (negative control) or LPS (100 ng/ml, positive
control) in order to mimic ex vivo the condition of airways
during COPD exacerbation in vivo [11–13].
Some LPS-incubated tissues were pre-treated with in-
creasing concentrations of NAC from very low to high
concentrations (10 nM, 100 nM, 1 μM, 3 μM, 10 μM,
30 μM, 100 μM, 300 μM, 1 mM and 10 mM) in order to
reproduce in the bath the plasmatic bioavailability fol-
lowing low and high oral doses of NAC [14–16]. Further
tissues were pre-treated with reduced GSH (100 μM), as
control for anti-oxidant activity [17–19].
The day after, bronchial rings were mounted into the
isolated organ bath system and connected to the isometric
force transducers for recording the contractile response of
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airway smooth muscle (ASM) in response to transmural
stimulation [20, 21].
Transmural stimulation
Transmural EFS was performed by placing tissues be-
tween two wire platinum electrodes (20 mm apart,
Panlab Harvard Apparatus, Spain), connected to a 3165
multiplexing pulse booster stimulator (Ugo Basile, VA -
Italy). Reference standard contraction was then assessed
for every bronchial ring by stimulating samples with a
train of 25Hz EFS impulses (10 V, 10 s, 0.5 ms). After
that, bronchial rings were contracted by EFS at increas-
ing frequencies (1, 3, 10, 25 and 50 Hz) in order to
simulate the vagal firing (parasympathetic pathway)
normally observed in human in vivo at physiological
frequency range [12, 22].
Pro- anti-oxidant factors and cytokines quantification
The supernatant from all treatments was collected in
order to assess the influence of NAC on the pro- and
anti-oxidant response and on the release of cytokines.
The pro-oxidant response was assessed by quantifying
the activity of peroxidase and the concentrations of
hydrogen peroxide, malondialdehyde and nitric oxide.
The protective response to oxidative stress was investi-
gated by measuring the total anti-oxidant capacity, GSH
and the superoxide dismutase activity. The levels of cy-
tokines such as IL-1β, IL-6, IL-8 and tumor necrosis fac-
tor (TNF)-α were also determined and compared with
the respiratory burst induced by the incubation with
LPS [7, 23, 24].
The quantification of pro- and anti-oxidant factors
and of cytokines were carried out by performing colori-
metric/fluorometric and ELISA assays characterized by
high sensitive detection limits and high specificity, in
agreement with manufacturers’ datasheets (BioCat,
Heidelberg, Germany).
Neurokinin A quantification
The collected supernatant was also used to quantify the
levels of neurokinin A (NKA) in response to LPS incu-
bation and NAC treatment. The quantification of NKA
was performed via ELISA assays in agreement with man-
ufacturers’ datasheets (BioCat, Heidelberg, Germany).
Data analysis
The contractile responses will be expressed as a percentage
of the maximal effect (Emax) induced by EFS in control
bronchi. Appropriate curve fitting to a sigmoidal model was
used to calculate the effect (E), the Emax, the dose inducing
n% Emax (ECn). The equation used was: log (agonist; antag-
onist) vss response, Variable slope, expressed as Y = Bottom
+ (Top - Bottom)/{1 + 10^[(LogEC50 - X)*HillSlop2]}. For
statistical analysis of the potency, the pEC50 value was used
where pEC50 =−logEC50 [25].
Linear regression was used for analyzing the effective-
ness of NAC as described elsewhere. The levels of NKA
were correlated (Pearson’s correlation and 95% CI) with
the pro- anti-oxidant factors and cytokines released by
isolated bronchi [25].
Experiments were performed on n = 4 bronchi col-
lected from different subjects and values presented as
mean ± SEM. In agreement with tissues availability and
vitality, each single treatment was carried out by using
specimens collected from the same patient, and experi-
ments were repeated 4 times in samples originating from
4 different donors. When the amount of sample from
one subject did not permit to perform all the treatments,
including the pre-treatment with increasing concentra-
tions of NAC, the remaining treatments were carried
out in specimens collected from other patients in paral-
lel with further positive and negative controls.
The evaluation of the pro- and anti-oxidant activity
and the quantification of cytokines were normalized for
100 mg of bronchial tissue and carried out by perform-
ing experiments repeated in triplicate.
The statistical significance was assessed by the t-test
or the two-way analysis of variance (ANOVA), and the
level of statistical significance will be defined as P < 0.05.
Data analysis was performed by using Prism 5 software
(GraphPad Software Inc, CA, USA).
Results
Influence of NAC on the bronchial desensitization
induced by LPS
The overnight incubation with LPS (100 ng/ml) induced
a significant (P < 0.05 vs. control) desensitization of hu-
man isolated bronchial rings on the contractile response
induced by EFS, whereas GSH (100 μM) completely
abolished this effect (P > 0.05 vs. control) (Emax: control
100.20 ± 21.32%, LPS 44.92 ± 12.70%, LPS + GSH 97.90
± 7.75%; Fig. 1a).
The concomitant incubation with NAC administered
at concentrations ranging from 10 nM to 3 μM did not
modulate the desensitizing effect induced by LPS (P >
0.05 vs. LPS-incubated bronchi). On the other hand,
higher concentrations of NAC significantly prevented
the LPS-induced desensitization (P < 0.05 vs. LPS-
incubated bronchi), thus restoring the physiological con-
tractile response elicited by EFS in isolated airways
(NAC 10 μM to 300 μM: Emax 86.39 ± 9.92% to 96.16 ±
27.43%; NAC 1 mM to 10 mM: Emax 105.20 ± 21.42% to
111.10 ± 18.55%; Fig. 1c and b).
The analysis of potency was carried out for EFS indu-
cing ≈ Emax in control airways, specifically EFS 25 Hz
and 50 Hz. NAC prevented the desensitization induced
by LPS incubation in a linear concentration-response
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manner, with analogous pEC50 values for both EFS
25 Hz and 50 Hz (5.45 ± 0.24 and 5.77 ± 0.42, respect-
ively; P > 0.05) (Fig. 2).
Influence of NAC on the pro- and anti-oxidant response
in LPS-incubated airways
The overnight incubation with LPS (100 ng/ml) signifi-
cantly increased the pro-oxidant response of human iso-
lated bronchi (peroxidase activity: +101.40 ± 3.58%;
hydrogen peroxide: +66.03 ± 2.79%; malondialdehyde
+29.36 ± 0.74%; nitric oxide: +46.59 ± 10.01; P < 0.001 vs.
control), and this effect was reduced by GSH (100 μM;
P < 0.001 vs. LPS-incubated bronchi). NAC administered
at medium-to-high concentrations (from 1 μM to
10 mM) significantly reduced the pro-oxidant response
induced by LPS (peroxidase activity: −32.03 ± 2.95%;
hydrogen peroxide: −39.50 ± 1.56%; malondialdehyde
−29.0.5 ± 0.54%; nitric oxide: −24.06 ± 1.79%; P < 0.05 vs.
LPS-incubated bronchi) (Fig. 3).
The incubation with LPS (100 ng/ml) significantly
reduced the anti-oxidant response of human isolated
bronchi (total anti-oxidant capacity: −18.85 ± 1.94%;
Fig. 1 Frequency-response curves produced by EFS ranging from 1 Hz to 50 Hz in control bronchi and after overnight incubation with LPS
(100 ng/ml), alone or together with GSH (100 μM) (a). Influence of increasing concentrations of NAC (b 10 nM to 10 μM; c 30 μM to 10 mM) on
the desensitizing effect induced by LPS (100 ng/ml). Data are expressed as the mean ± SEM of n= 4 segmental bronchi from different subjects. # P< 0.05 vs.
control bronchi: * P< 0.05 and **P< 0.01 vs. LPS-incubated bronchi (statistical significance assessed by two-way ANOVA for comparison among control, LPS,
LPS +GSH and LPS +NAC treatments)
Fig. 2 Linear concentration-response curves by NAC on the desensitization induced by overnight incubation of human isolated bronchi with LPS
(100 ng/ml). Data are expressed as the mean ± SEM contractile response to EFS delivered at 25 Hz (a) and 50 Hz (b) in n = 4 segmental bronchi
from different subjects
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GSH: −29.76 ± 2.87%; superoxide dismutase: −44.82 ±
6.15%). The pre-treatment with GSH (100 μM) signifi-
cantly prevented the anti-oxidant impairment response
(P < 0.001 vs. LPS-incubated bronchi). NAC adminis-
tered at medium-to-high concentrations (from 1 μM to
10 mM) was effective in preventing the reduced anti-
oxidant response induced by LPS (total anti-oxidant cap-
acity: +92.91 ± 6.61%; GSH: +49.56 ± 3.53%; superoxide
dismutase: +150.40 ± 19.51%; P < 0.001 vs. LPS-
incubated bronchi) (Fig. 4).
Influence of NAC on the release of cytokines in LPS-
incubated airways
The overnight incubation with LPS (100 ng/ml) signifi-
cantly increased the release of cytokines in human iso-
lated airways (IL-1β: +331.24 ± 17.03%; IL-6: +67.32 ±
7.28%; IL-8: +260.00 ± 17.50%; TNF-α: +3166.26 ±
545.77%; P < 0.001 vs. control), and this effect was re-
duced by GSH (100 μM; P < 0.001 vs. LPS-incubated
bronchi). NAC administered at high concentrations
(from 300 μM to 10 mM) significantly inhibited the re-
lease of IL-1β (−33.62 ± 2.10%), IL-8 (−68.11 ± 17.34%)
and TNF-α (−62.82 ± 10.34%), when compared with
LPS-incubated bronchi (P < 0.01). Lower concentrations
of NAC (from 1 μM to 10 mM) were significantly (P <
0.001) effective in reducing the release of IL-6 (−33.16 ±
2.02%) induced by the stimulation with LPS (Fig. 5).
Influence of NAC on the release of neurokinin A in LPS-
incubated airways
The overnight incubation with LPS (100 ng/ml) induced
a significantly release of NKA (+71.75 ± 3.04%; P < 0.001
vs. control). NAC administered at high concentrations
(from 10 μM to 10 mM) significantly inhibited the re-
lease of NKA (−31.90 ± 2.37%), when compared with
LPS-incubated bronchi (P < 0.001) (Fig. 6).
The release of NKA was positively correlated with the
levels of pro-oxidant factors (peroxidase activity, H2O2,
malondialdehyde [MDA], nitric oxide [NO]; P < 0.05)
and concentrations of the cytokine IL-6 (P < 0.05),
Fig. 3 Influence of NAC on the pro-oxidant response (a peroxidase activity, b H2O2 concentrations, cmalondialdehyde [MDA] concentrations and d nitric
oxide concentrations) induced by overnight incubation of human isolated bronchi with LPS (100 ng/ml). Horizontal dotted lines indicate the pro-oxidant
response in control bronchi (c), in bronchi treated with LPS alone or in the presence of GSH. Data are expressed as the mean± SEM of experiments repeated
in triplicate. * P<0.05 and ***P< 0.001 vs. LPS-incubated bronchi (statistical significance assessed by two-way ANOVA)
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Fig. 4 Influence of NAC on the anti-oxidant response (a total anti-oxidant capacity [TAC], b GSH concentrations and c superoxide dismutase
[SOD] activity) induced by overnight incubation of human isolated bronchi with LPS (100 ng/ml). Horizontal dotted lines indicate the anti-oxidant
response in control bronchi (c), in bronchi treated with LPS alone or in the presence of GSH. In B the LPS + GSH treatment has been not carried
out in order to not influence the GSH quantification. Data are expressed as the mean ± SEM of experiments repeated in triplicate. ***P < 0.001 vs.
LPS-incubated bronchi (statistical significance assessed by two-way ANOVA). ND: not detectable
Fig. 5 Influence of NAC on the cytokines release (a IL-1β concentrations, b IL-6 concentrations, c IL-8 concentrations and d TNF-α concentrations)
induced by overnight incubation of human isolated bronchi with LPS (100 ng/ml). Horizontal dotted lines indicate the cytokines concentrations in
control bronchi (c), in bronchi treated with LPS alone or in the presence of GSH. Data are expressed as the mean ± SEM of experiments repeated in
triplicate. **P < 0.01 and ***P < 0.001 vs. LPS-incubated bronchi (statistical significance assessed by two-way ANOVA)
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whereas it was negatively correlated with the levels of
the anti-oxidant factor GSH (P < 0.05). No significant
correlation was found for total anti-oxidant (TAC),
superoxide dismutase (SOD), IL-1β, IL-8, and TNF-α
(P > 0.05) (Table 1).
Discussion
The role of ASM has been the subject of provocative
commentaries, proposing that ASM is a useless, vestige
of phylogeny, perhaps retained only because of its
common ontogenetic origin with the gut [26–29].
Nevertheless, an elegant analysis showed how ASM is
useful [26]. In fact, ASM is part of an alarm system, akin
to allergic pruritus, warning us of exposures to danger-
ous toxins and allergens to which we might otherwise be
sensitive. The primary function of ASM is to contract,
which regulates airway tone and bronchial narrowing
[27, 30–32]. Although complete airway closure is fatal,
uncomfortable partial closure is likely to provide life-
preserving function [26]. Further roles for ASM consist
of peristalsis to assist exhalation and mucus propulsion,
promotion of lymphatic and venous flow, ventilation/
perfusion matching, protection of peripheral lung and
airway architecture, enhancement of the effectiveness of
cough, optimization of anatomic dead space volume, and
modulation of immune and proliferative responses
[27, 30]. Therefore, while no single role for ASM con-
tributes a large adaptive advantage, cumulatively they
provide a distinct benefits [26]. Taken together, these ev-
idences clearly indicate that a physiological bronchial
contractility is necessary to protect the airways from the
insult of external pathogens.
The results of our study demonstrate that the over-
night challenge of human isolated airways with LPS
100 ng/ml induces bronchial desensitization, and NAC
counteracts this desensitization by restoring the physio-
logical contractility of ASM, at least in an ex vivo model
of COPD exacerbation. This finding suggests that NAC
may preserve the normal bronchoreactivity in COPD pa-
tients that are chronically colonized by Gram-negative
bacteria, leading to protection against exacerbations.
Previous researches reported that the acute challenge
of human isolated tissues with LPS administered at
300 ng/ml for 2 h induced bronchial hyperresponsive-
ness (BHR) [12, 33]. Actually, the acute activation of sen-
sory c-fibers by endotoxin and capsaicin provokes BHR
due to the facilitation of cholinergic pathway driven by
vagus nerve [33, 34]. Thus, although the desensitizing ef-
fect of overnight exposure to LPS may appear paradoxical,
it had to be expected since also multiple challenges with
capsaicin led to bronchial desensitization [21].
Results of our experiments suggest that also other
pharmacological characteristics of NAC, such as the anti-
oxidant and anti-inflammatory activities, may explain the
protective role with regard of COPD exacerbations.
GSH is a carrier of active thiol group in form of a
cysteine (Cys) residue, and acts as an antioxidant by
interacting with reactive oxygen/nitrogen species and
electrophiles and operating as a cofactor for various en-
zymes [1]. The loss of antioxidant capacity in oxidatively
stressed cells/tissues is related to a decrease in GSH
and/or its precursor Cys. Cys cannot be used as a GSH
precursor due to its toxicity at high concentrations, and
also because it is susceptible to metabolism and rapid
Fig. 6 Influence of NAC on the release of neurokinin A (NKA)
induced by overnight incubation of human isolated bronchi with
LPS. Data are expressed as the mean± SEM of experiments repeated in
triplicate. ***P< 0.001 vs. LPS-incubated bronchi (statistical significance
assessed by two-way ANOVA)
Table 1 Correlation between NKA concentrations and levels of pro-
oxidant factors, anti-oxidant factors and cytokines after overnight
incubation with LPS (100 ng/ml)
NKA vs: Pearson r 95% CI P
Peroxidase activity 0.85 0.47 - 0.96 ***
H2O2 0.84 0.44 - 0.96 **
MDA 0.63 0.01 - 0.90 *
NO 0.83 0.41 - 0.96 **
TAC −0.49 −0.86 - 0.20 ns
GSH −0.63 −0.91 - 0.058 *
SOD −0.28 −0.77 - 0.43 ns
IL-1β 0.13 −0.55 - 0.70 ns
IL-6 0.82 0.4 0–0.96 **
IL-8 0.30 −0.40 - 0.78 ns
TNF-α 0.19 −0.50 - 0.73 ns
* P<0.05, ** P<0.01, *** P<0.001, ns: not significant. GSH glutathione, IL
interleukin, MDA malondialdehyde, NKA neurokinin A, NO nitric oxide, ROS
reactive oxygen species, SOD superoxide dismutase, TAC total anti-oxidant
capacity, TNF-α tumor necrosis factor-α
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oxidation, generating the inactive disulphide cystine
(Cys–Cys) [35, 36]. GSH concentrations are increased in
BALF of patients with stable COPD, and reduced in
course of exacerbations [2]. This evidence suggests that
the increase of lung GSH may be an attempt to counter-
act the excessive oxidant production, attempt totally in-
adequate during exacerbations due to the excessive
production of ROS [1].
NAC acts as a precursor for the substrate Cys in the
synthesis of GSH, by delivering sulfhydryl moieties for
utilization in biological processes [37]. In fact, NAC may re-
store the pool of intracellular GSH that has been depleted
following increased status of oxidative stress and inflamma-
tion in course of COPD exacerbation, by modulating the ac-
tivity of redox-sensitive cell-signaling and transcription
pathways such as the Nuclear Factor-kB [38].
Although from a strict biochemical point of view the
antioxidant activity of NAC has been proved to be both
direct (the free sulfhydryl group may serve as a ready
source of reducing equivalents) and indirect (through re-
plenishment of intracellular GSH levels), the real impact
of NAC on the imbalance between oxidative stressors
and anti-oxidants in the human bronchial tissue has
been never investigated before. Here, we have ultimately
demonstrated that NAC is effective in improving the
antioxidant activity and reducing ROS elevation in hu-
man airways in course of a validated model of COPD
exacerbation.
The possible pathways through which NAC can modu-
late inflammation have been suggested taking into ac-
count the data obtained in in vitro studies, but to date
discordant findings still exist in vivo [7]. Sadowska and
colleagues [7] suggested that this discrepancy might be
explained by the fact that the effects of NAC are cell
specific and concentration-dependent. The authors also
highlighted that the concentrations necessary to elicit
anti-inflammatory effects are higher than those required
for an anti-oxidant response, and that higher doses are
needed to achieve acute anti-oxidant and anti-
inflammatory effects [7]. Our results confirm these hy-
potheses. In fact, we have demonstrated that the concen-
trations of NAC necessary to elicit anti-inflammatory
effects in human bronchi stimulated by LPS were at least
one logarithm higher than those required to improve the
antioxidant capacity. This gradient of effectiveness indi-
cates that perhaps the anti-inflammatory effect of NAC
is secondary to its antioxidant activity.
Nevertheless, we cannot omit to highlight that NAC
administered at only 1 μM, a concentration able to in-
duce effective anti-oxidant effect, was also enough to
prevent IL-6 elevation. This result implies that, while
higher concentrations of NAC may modulate the release
of cytokines such as IL-1β, IL‐8 and TNF‐α by inhibiting
oxidative stress, some further mechanisms that go
beyond the anti-oxidant activity may regulate the IL-6
increase, in particular when NAC is administered at
lower concentrations.
Specifically, our findings suggest that NAC might
modulate the neurogenic inflammatory response in-
duced by LPS through the inhibition of NKA release,
and thus reduce IL-6 increase. Although the role of
LPS in increasing the neurogenic inflammation has
been widely demonstrated in airways [12, 33, 34], we
cannot exclude that IL-6 itself might induce a further
enhancement of NKA release, as demonstrated in the
hypothalamic-pituitary axis [39]. Intriguingly, our
study confirms that very low concentrations of NKA
might play a pivotal role in fine-tuning BHR in
human tissues.
Our study cannot discriminate whether the neurogenic
inflammation induced by LPS led to oxidative stress or
vice versa. Nevertheless, it is clear that both ROS forma-
tion and neurogenic inflammation are critical conse-
quences of an exposure to LPS, a typical condition of
acute COPD exacerbation that is also characterized by
significantly increased levels of IL-6 [40].
Overall, the findings of the present study corroborate
the opinion that NAC may be effective in reducing COPD
exacerbations not only via its indirect anti-oxidant activity,
but also by inducing an anti-inflammatory effect second-
ary to an improved anti-oxidant capacity. Furthermore,
they support the possibility that NAC can even act by
modulating the neurogenic inflammation, a deleterious
condition that may support the vicious circle between oxi-
dative stress and inflammation.
Plasma concentrations of NAC reaches values of ≈
5 μM after oral administration of 200 mg, ≈16 μM
after oral administration of 600 mg, and ≈ 35 μM after
an oral administration of 1,200 mg [14, 41, 42].
Therefore, the results of our study confirm that NAC
administered at 600 mg may elicit prevalently anti-
oxidant activity, whereas higher doses are necessary
to produce anti-inflammatory effect. This consider-
ation is in agreement with the results of a recent
meta-analysis advising that in a patient suffering from
COPD with an objective confirmation of airways ob-
struction NAC should always be administered at a
dose ≥1200 mg per day to prevent COPD exacerba-
tions, while in a patient with chronic bronchitis, but
without airway obstruction, a regular treatment of
600 mg per day seems to be sufficient [5].
Conclusion
The findings of this study suggest that NAC may have a
role in modulating the detrimental effect induced by
LPS in course of COPD exacerbation. It may elicit both
anti-oxidant and anti-inflammatory effects when admin-
istered at high concentrations.
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